nach oben

Erschienen in:

01.03.2016 | Original Article

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance

verfasst von: Quan Zhang, Tianyu Sun, Poming Kang, Kai Qian, Bo Deng, Jinghai Zhou, Ruwen Wang, Bin Jiang, Kun Li, Fang Liu, Shiyang Wu, Qunyou Tan

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The assessment of single gene such as ERCC1, TYMS, RRM1, TUBB3, EGFR, KRAS, BRAF, PIK3CA, ALK, and ROS1 is now widely applied in therapeutic decisions of non-small cell lung cancer (NSCLC). The aim of our study was to concurrently analyze these genes and evaluate their clinical significance in patients with NSCLC.

Methods

Rearrangement of ALK and ROS1 was analyzed in 120 patients using FISH assays. Somatic mutation of EGFR, KRAS, BRAF, PIK3CA and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR were examined by liquidchip platform in 350 patients . Data on clinical features were obtained from medical records of 119 patients, and the follow-up was conducted in 106 patients who received platinum-based adjuvant chemotherapy.

Results

We identified 5.0 % ALK rearrangements, 1.7 % ROS1 rearrangements, 36.6 % EGFR mutations, 8.9 % KRAS mutations, 0 % BRAF mutations, and 4.0 % PIK3CA mutations. Double or coexisting mutations were identified in 13 patients. Significant correlations were observed among EGFR, KRAS mutation, ERCC1, TYMS, RRM1, TUBB3, EGFR expression, and clinical features, especially histology (P < 0.05). Significant cross-correlations were observed in some pairs of genes (P < 0.05). Patients with low RRM1 expression had a better progression-free survival (PFS) (P < 0.05). Furthermore, EGFR-mutated patients with low RRM1 expression or patients with both ERCC1 and RRM1 low expression had a better PFS (P < 0.05).

Conclusion

Combined analysis of these commonly studied genes may promote the individual treatment in NSCLC. RRM1 may be a prognostic and predictive biomarker for PFS in patients with NSCLC who received platinum-based adjuvant chemotherapy, and combining EGFR mutation and RRM1 expression or combining ERCC1 and RRM1 expression can enhance prognostic and predictive power for PFS.

D’addario G, Früh M, Reck M et al (2010) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116–v119. doi:10.1093/annonc/mdq189 CrossRefPubMed

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262 CrossRefPubMed

Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32(4):605–644. doi:10.1016/j.ccm.2011.09.001 CrossRefPubMed

Zhou C (2014) Lung cancer molecular epidemiology in China: recent trends. Trans Lung Cancer Res 3(5):270–279. doi:10.3978/j.issn.2218-6751.2014.09.01

Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004–1012. doi:10.1016/S1470-2045(11)70232-7 PubMedCentralCrossRefPubMed

Shaw AT, Ou SHI, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small cell lung cancer. N Engl J Med 371(21):1963–1971. doi:10.1056/NEJMoa1406766 PubMedCentralCrossRefPubMed

Dahabreh IJ, Linardou H, Kosmidis P et al (2011) EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Ann Oncol 22(3):545–552. doi:10.1093/annonc/mdq432 CrossRefPubMed

Petrelli F, Borgonovo K, Cabiddu M, Barni S (2012) Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 13(2):107–114. doi:10.1016/j.cllc.2011.08.005 CrossRefPubMed

Pirker R, Pereira JR, von Pawel J et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33–42. doi:10.1016/S1470-2045(11)70318-7 CrossRefPubMed

10.

Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17. doi:10.1371/journal.pmed.0020017 PubMedCentralCrossRefPubMed

11.

Lin L, Bivona TG (2012) Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012:817297. doi:10.1155/2012/817297 PubMedCentralPubMed

12.

Ludovini V, Bianconi F, Pistola L et al (2011) Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 6(4):707–715. doi:10.1097/JTO.0b013e31820a3a6b CrossRefPubMed

13.

Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small cell lung cancer: a systematic review and meta-Analysis. Clin Lung Cancer 12(6):393–401. doi:10.1016/j.cllc.2011.04.005 PubMedCentralCrossRefPubMed

14.

Wang T, Chuan Pan C, Rui YuJ et al (2013) Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis. PLoS One 8(9):e74284. doi:10.1371/journal.pone.0074284 PubMedCentralCrossRefPubMed

15.

Gong W, Zhang X, Wu J et al (2012) RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small cell lung cancer: a meta-analysis. Lung Cancer 75(3):374–380. doi:10.1016/j.lungcan.2011.08.003 CrossRefPubMed

16.

Zhang HL, Ruan L, Zheng LM et al (2012) Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1):9–15. doi:10.1016/j.lungcan.2012.01.005 CrossRefPubMed

17.

Wang Y, Liu ZD, Zhao LM et al (2012) Individualized treatment of NSCLC: from research to clinical practice. Neoplasma 60(5):538–545. doi:10.4149/neo_2013_070 CrossRef

18.

An S-J, Chen Z-H, Su J et al (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 7(6):e40109. doi:10.1371/journal.pone.0040109 PubMedCentralCrossRefPubMed

19.

Kim HR, Shim HS, Chung JH et al (2012) Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118(3):729–739. doi:10.1002/cncr.26311 CrossRefPubMed

20.

Kim HR, Lim SM, Kim HJ et al (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24(9):2364–2370. doi:10.1093/annonc/mdt220 CrossRefPubMed

21.

Li G, Luo X, He J et al (2011) A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 49(2):191–195. doi:10.1515/CCLM.2011.040 PubMed

22.

Leach B (2011) FDA approves crizotinib for late-stage non-small cell lung cancer. August 26, 2011. http://www.onclive.com/web-exclusives/FDA-Approves-Crizotinib-for-Late-Stage-Non-Small-Cell-Lung-Cancer. Accessed 30 Sept 2011

23.

National Comprehensive Cancer Network (2013) NCCN clinical practice guidelines in oncology: non-small cell lung cancer (version 2.2013). National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

24.

Rimkunas VM, Crosby KE, Li D et al (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18(16):4449–4457. doi:10.1158/1078-0432.CCR-11-3351 CrossRefPubMed

25.

Li S, Li L, Zhu Y et al (2014) Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 110(11):2812–2820. doi:10.1038/bjc.2014.210 PubMedCentralCrossRefPubMed

26.

Chen YR, Fu YN, Lin CH et al (2006) Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25(8):1205–1215. doi:10.1038/sj.onc.1209159 CrossRefPubMed

27.

Yee-San Tam I, Leung ELH, Tin VPC et al (2009) Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 8(8):2142–2151. doi:10.1158/1535-7163.MCT-08-1219 CrossRefPubMed

28.

Wang L, Hu H, Pan Y et al (2014) PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 9(2):e88291. doi:10.1371/journal.pone.0088291 PubMedCentralCrossRefPubMed

29.

Choughule A, Sharma R, Trivedi V et al (2014) Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. Br J Cancer 111:2203–2204. doi:10.1038/bjc.2014.401 PubMedCentralCrossRefPubMed

30.

Lu HY, Su D, Pan XD et al (2012) Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer. Oncol Lett 3(2):415–420. doi:10.3892/ol.2011.502 PubMedCentralPubMed

31.

Maus MKH, Mack PC, Astrow SH et al (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small cell lung cancer: implications for therapy. J Thorac Oncol 8(5):582–586. doi:10.1097/JTO.0b013e318287c3c5 CrossRefPubMed

32.

Koh Y, Jang B, Han SW et al (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 5(3):320–325. doi:10.1097/JTO.0b013e3181ce684f CrossRefPubMed

33.

Shaw AT, Yeap BY, Mino-Kenudson M et al (2009) Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247–4253. doi:10.1200/JCO.2009.22.6993 PubMedCentralCrossRefPubMed

34.

Douillard JY, Shepherd FA, Hirsh V et al (2010) Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28(5):744–752. doi:10.1200/JCO.2009.24.3030 CrossRefPubMed

35.

Park JH, Lee SH, Keam B et al (2012) EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 77(2):433–437. doi:10.1016/j.lungcan.2012.03.020 CrossRefPubMed

36.

Wu SG, Yang CH, Yu CJ et al (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72(3):333–339. doi:10.1016/j.lungcan.2010.10.012 CrossRefPubMed

37.

Campos-Parra AD, Zuloaga C, Manríquez MEV et al (2015) KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol 38(1):33–40. doi:10.1097/COC.0b013e318287bb23 CrossRefPubMed

38.

Jensen JD, Knoop A, Laenkholm AV et al (2012) PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23(8):2034–2042. doi:10.1093/annonc/mdr546 CrossRefPubMed

39.

Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10(4):1318–1325. doi:10.1158/1078-0432.CCR-03-0156 CrossRefPubMed

40.

Zhao H, Zhang H, Du Y, Gu X (2014) Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumor Biol 35(12):12679–12688. doi:10.1007/s13277-014-2592-7 CrossRef

Titel: Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance
verfasst von: Quan Zhang
Tianyu Sun
Poming Kang
Kai Qian
Bo Deng
Jinghai Zhou
Ruwen Wang
Bin Jiang
Kun Li
Fang Liu
Shiyang Wu
Qunyou Tan
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-2969-y

Springer Medizin

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance